Phase Forward Appoints Michael Owings Chief Privacy Officer
December 15 2009 - 9:00AM
Business Wire
Phase Forward (NASDAQ: PFWD), a leading provider of data
management solutions for clinical trials and drug safety, today
announced that Michael Owings has been appointed to the newly
created role of chief privacy officer. Owings, 55, has held the
position of vice president, quality and regulatory compliance at
Phase Forward since 2004, and will continue in that related
role.
As chief privacy officer, Owings will be responsible for all
privacy and data protection policies and best practices affecting
Phase Forward’s customers, partners and employees, and ensuring
compliance with all relevant regulations. He has been accredited as
a Certified Information Privacy Professional through the
International Association of Privacy Professionals.
“In his nine years with Phase Forward, Michael has been
instrumental in building the company’s reputation as a leader in
regulatory compliance,” said Bob Weiler, chairman and CEO of Phase
Forward. “This new role is a natural extension of Michael’s
in-depth knowledge of compliance issues, and he will help to ensure
that our policies and products meet the highest possible standards
for processing and storing sensitive data.”
“I look forward to this new role, particularly in light of the
challenges customers are facing in an increasingly complex
regulatory environment,” said Owings. “My mission is to help ensure
that Phase Forward continues to be an expert resource for our
customers regarding the latest standards and policies in this
fast-changing area.”
Prior to becoming a vice president at Phase Forward, Owings
served as director, quality and regulatory affairs from 2002 to
2004, and in other quality affairs and regulatory management roles
at the company from 2000 to 2002. Prior to joining Phase Forward,
Owings held various positions at Copley Pharmaceutical, at Procept
and at Marion Merrell Dow (HMR/Aventis).
About Phase Forward
Phase Forward is a leading provider of integrated data
management solutions for clinical trials and drug safety. Phase
Forward’s products and services have been utilized in over 10,000
clinical trials involving more than 1,000,000 clinical trial study
participants at over 300 organizations and regulatory agencies
worldwide including: AstraZeneca, Boston Scientific, Dana-Farber
Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration,
GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono,
Novartis, Novo Nordisk, PAREXEL International, Procter &
Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, SGS, Tibotec and the U.K. Medicines and
Healthcare Products Regulatory Agency. Additional information about
Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. This press release
contains express or implied forward-looking statements relating to,
among other things, continued service of its executive personnel
and its ability to stay abreast of evolving regulatory standards.
These statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are
beyond Phase Forward's control, which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. In particular, the risks and uncertainties include,
among other things, changes in laws and regulations affecting Phase
Forward’s customers and the ability of Phase Forward to retain its
executive personnel. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Phase Forward
undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise. For
additional disclosure regarding these and other risks faced by
Phase Forward, see the disclosure contained in Phase Forward's
public filings with the Securities and Exchange Commission
including, without limitation, its most recent Annual Report on
Form 10-K.
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Phase Forward (NASDAQ:PFWD)
Historical Stock Chart
From Jul 2023 to Jul 2024